Nippon Shokubai to Boost Nucleic Acid Drug API Output Tenfold
Nippon Shokubai recently announced plans to expand its GMP-compliant manufacturing capacity for nucleic acid drug active pharmaceutical ingredients (APIs) tenfold, in response to the rapidly growing global demand in the nucleic acid drug market.
The global market for nucleic acid drugs is projected to exceed 1,400 billion yen (€8.2 billion) by 2030. In line with this, the global CDMO market for nucleic acid drugs is expected to grow at an average annual rate of 14% from 2021 to 2030, reaching 200 billion yen (€1.2 billion) by 2030. Against this backdrop of market expansion, pharmaceutical companies in Japan and abroad have expressed strong expectations for the enhancement of our GMP-compliant manufacturing facilities.
This capacity expansion will involve the installation of a large-scale production line with ten times the capacity (several kilograms per batch) of Nippon Shokubai's existing line. The new facility is scheduled to begin operation in 2027. With this, Nippon Shokubai will become one of Japan’s largest CDMOs, capable of manufacturing nucleic acid drug APIs for common diseases that require large-scale supply. It will strengthen its manufacturing system to meet a wide range of needs, from non-clinical stages to large-scale commercial production.
